- Home
- CDE vs BLTE Comparison
CDE vs BLTE Comparison
Compare CDE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- BLTE
- Stock Information
- Founded
- CDE 1928
- BLTE 2018
- Country
- CDE United States
- BLTE United States
- Employees
- CDE N/A
- BLTE N/A
- Industry
- CDE Precious Metals
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- CDE Basic Materials
- BLTE Health Care
- Exchange
- CDE Nasdaq
- BLTE Nasdaq
- Market Cap
- CDE 2.5B
- BLTE 2.1B
- IPO Year
- CDE N/A
- BLTE 2022
- Fundamental
- Price
- CDE $6.03
- BLTE $56.40
- Analyst Decision
- CDE Strong Buy
- BLTE Strong Buy
- Analyst Count
- CDE 4
- BLTE 4
- Target Price
- CDE $8.00
- BLTE $96.67
- AVG Volume (30 Days)
- CDE 19.5M
- BLTE 37.7K
- Earning Date
- CDE 05-07-2025
- BLTE 05-12-2025
- Dividend Yield
- CDE N/A
- BLTE N/A
- EPS Growth
- CDE N/A
- BLTE N/A
- EPS
- CDE 0.15
- BLTE N/A
- Revenue
- CDE $1,054,006,000.00
- BLTE N/A
- Revenue This Year
- CDE $49.05
- BLTE N/A
- Revenue Next Year
- CDE $10.38
- BLTE N/A
- P/E Ratio
- CDE $40.20
- BLTE N/A
- Revenue Growth
- CDE 28.35
- BLTE N/A
- 52 Week Low
- CDE $4.03
- BLTE $32.25
- 52 Week High
- CDE $7.72
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- CDE 53.07
- BLTE 39.21
- Support Level
- CDE $5.69
- BLTE $49.00
- Resistance Level
- CDE $6.51
- BLTE $60.21
- Average True Range (ATR)
- CDE 0.45
- BLTE 3.55
- MACD
- CDE 0.08
- BLTE -0.57
- Stochastic Oscillator
- CDE 75.13
- BLTE 41.67
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.